Patents by Inventor Paul Brian Little

Paul Brian Little has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDINE DERIVATIVES AS MODULATORS OF SORTILIN ACTIVITY
    Publication number: 20240132514
    Abstract: The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment or prevention of medical conditions where modulation of sortilin activity is beneficial.
    Type: Application
    Filed: January 20, 2022
    Publication date: April 25, 2024
    Inventors: Paul Brian LITTLE, Manuel Javier CASES-THOMAS, Mads Fuglsang KJØLBY, Anders NYKJÆR
  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11591284
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 28, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190185409
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.
    Type: Application
    Filed: December 14, 2017
    Publication date: June 20, 2019
    Applicant: NMD Pharma ApS
    Inventors: Lars J.S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183812
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. Knutsen, Nicholas M. Kelly, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • Y4 selective receptor agonists for therapeutic interventions
    Patent number: 8022035
    Abstract: Y4 receptor agonist peptide selected from the group consisting of: [Ala30]PP2-36, [Thr30]PP2-36, [Asn30]PP2-36, [Gln30]PP2-36, [Glu10]PP2-36, [Glu10,Leu17,Thr30]PP2-36, [Nle17,Nle30]PP2-36, [Glu10,Nle17,Nle30]PP2-36, their PP1-36 equivalents, and analogues and derivatives thereof as described in the specification, are selective agonists of the Y4 receptor relative to the Y1 and Y2 receptors, and are useful in the treatment, for example, of obesity and overweight, and conditions in which these are considered contributory factors, and in the treatment of diarrhoea and intestinal hypersecretion.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: September 20, 2011
    Assignee: 7TM Pharma A/S
    Inventors: Thue Schwartz, Paul Brian Little, Lars-Ole Gerlach, Christian Elling
  • Y-RECEPTOR AGONISTS
    Publication number: 20100160226
    Abstract: Human Pancreatic Polypeptide mutants are provided which have utility, inter alia, for regulation of energy intake or energy metabolism, control of intestinal secretion, decrease of gastrointestinal tract motility, decrease of rate of gastric emptying, treatment of obesity or overweight, or conditions in which obesity or overweight is a contributory factor.
    Type: Application
    Filed: April 21, 2008
    Publication date: June 24, 2010
    Applicant: 7TM PHARMA A/S
    Inventors: Thue Schwartz, Christian Elling, Paul Brian Little, Anders Heding, Lars-Ole Gerlach
  • Y4 SELECTIVE RECEPTOR AGONISTS FOR THERAPEUTIC INTERVENTIONS
    Publication number: 20090118178
    Abstract: Y4 receptor agonist peptide selected from the group consisting of: [Ala30]PP2-36, [Thr30]PP2-36, Asn30]PP2-36, [Gln30]PP2-36, [Glu10]PP2-36, [Glu10,Leu17,Thr30]PP2-36, [Nle17,Nle30]PP2-36, [Glu10,Nle17,Nle30]PP2-36, their PP1-36 equivalents, and analogues and derivatives thereof as described in the specification, are selective agonists of the Y4 receptor relative to the Y1 and Y2 receptors, and are useful in the treatment, for example, of obesity and overweight, and conditions in which these are considered contributory factors, and in the treatment of diarrhoea and intestinal hypersecretion.
    Type: Application
    Filed: September 21, 2005
    Publication date: May 7, 2009
    Applicant: 7TM PHARMA A/S
    Inventors: Thue Schwartz, Paul Brian Little, Lars-Ole Gerlach, Christian Elling